Differential Target Multiplexed Spinal Cord Stimulation in Patients with Persistent Spinal Pain Syndrome Type II: a Study Protocol for a 12-month Multicentre Cohort Study (DETECT)

Overview

Journal BMJ Open

Specialty General Medicine

Date 2024 Nov 9

PMID 39521475

Authors

Lisa Goudman

Ann De Smedt

Sam Eldabe

Philippe Rigoard

Maxime Billot

Manuel Roulaud

Maarten Moens

Affiliations

Soon will be listed here.

Abstract

Introduction: Differential target multiplexed spinal cord stimulation (DTM SCS) is a new stimulation paradigm for chronic pain management with the aim of modulating glial cells and neurons in order to rebalance their interactions. Animal studies revealed positive effects of this type of stimulation; however, studies in humans are still scarce, pointing towards the need for an evaluation of the effectiveness and safety of DTM SCS in clinical settings. Furthermore, the differential target multiplexed (DTM) algorithm consists of a combination of several programmes, which will presumably consume more energy from the spinal cord stimulation (SCS) battery. Therefore, the objective of DETECT is to investigate the feasibility, effectiveness and safety of DTM SCS in patients with Persistent Spinal Pain Syndrome Type II through a longitudinal cohort study.

Methods And Analysis: DETECT is a prospective multicentre cohort study (n≥250) with a follow-up until 12 months after receiving DTM SCS. The study initiated in October 2021 and is currently still recruiting patients. Self-reporting outcome variables were evaluated at baseline (before SCS) and at 1, 6 and 12 months of DTM SCS. The primary effectiveness endpoint is overall pain intensity, measured with the visual analogue scale. Secondary effectiveness outcome measures are back pain intensity, leg pain intensity, disability, health-related quality of life, pain medication use, functional disability, clinical holistic responder status, self-management, impression of change, work status, pain catastrophising, symptoms of central sensitisation, anxiety, depression and healthcare utilisation. Time spent in different body postures and SCS stimulation parameters will be read out from the pulse generator. The prevalence of technical issues, recharge frequency, (serious) adverse events and the proportion of successful DTM trials will be collected as well. Longitudinal mixed models will be calculated to evaluate the effectiveness of DTM SCS over time.

Ethics And Dissemination: The study protocol was approved by the central Ethics Committee of the Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (B.U.N.1432021000563) and the Ethics Committees of each participating centre. Research findings will be disseminated to key stakeholders through peer-reviewed publications in scientific journals and presentations to clinical audiences.

Trial Registration Number: NCT05068011.

References

Vallejo R, Kelley C, Gupta A, Smith W, Vallejo A, Cedeno D . Modulation of neuroglial interactions using differential target multiplexed spinal cord stimulation in an animal model of neuropathic pain. Mol Pain. 2020; 16:1744806920918057. PMC: 7160773. DOI: 10.1177/1744806920918057. View

Tanei T, Maesawa S, Nishimura Y, Nagashima Y, Ishizaki T, Ando M . Efficacy of the latest new stimulation patterns of spinal cord stimulation for intractable neuropathic pain compared to conventional stimulation: study protocol for a clinical trial. Trials. 2023; 24(1):604. PMC: 10517501. DOI: 10.1186/s13063-023-07637-x. View

Cedeno D, Smith W, Kelley C, Vallejo R . Spinal cord stimulation using differential target multiplexed programming modulates neural cell-specific transcriptomes in an animal model of neuropathic pain. Mol Pain. 2020; 16:1744806920964360. PMC: 7710394. DOI: 10.1177/1744806920964360. View

Schultz D, Webster L, Kosek P, Dar U, Tan Y, Sun M . Sensor-driven position-adaptive spinal cord stimulation for chronic pain. Pain Physician. 2012; 15(1):1-12. View

Fishman M, Calodney A, Kim P, Slezak J, Benyamin R, Rehman A . Prospective, Multicenter Feasibility Study to Evaluate Differential Target Multiplexed Spinal Cord Stimulation Programming in Subjects With Chronic Intractable Back Pain With or Without Leg Pain. Pain Pract. 2020; 20(7):761-768. DOI: 10.1111/papr.12908. View

Goudman L, De Smedt A, Linderoth B, Eldabe S, Witkam R, Henssen D . Identifying goals in patients with chronic pain: A European survey. Eur J Pain. 2021; 25(9):1959-1970. DOI: 10.1002/ejp.1814. View

Manca A, Hawkins N, Sculpher M . Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2004; 14(5):487-96. DOI: 10.1002/hec.944. View

Cedeno D, Kelley C, Chakravarthy K, Vallejo R . Modulation of Glia-Mediated Processes by Spinal Cord Stimulation in Animal Models of Neuropathic Pain. Front Pain Res (Lausanne). 2022; 2:702906. PMC: 8915735. DOI: 10.3389/fpain.2021.702906. View

Jensen M, Karoly P, Braver S . The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986; 27(1):117-126. DOI: 10.1016/0304-3959(86)90228-9. View

10.

Smith W, Cedeno D, Thomas S, Kelley C, Vetri F, Vallejo R . Modulation of microglial activation states by spinal cord stimulation in an animal model of neuropathic pain: Comparing high rate, low rate, and differential target multiplexed programming. Mol Pain. 2021; 17:1744806921999013. PMC: 7925954. DOI: 10.1177/1744806921999013. View

11.

Chapman J, Norvell D, Hermsmeyer J, Bransford R, DeVine J, McGirt M . Evaluating common outcomes for measuring treatment success for chronic low back pain. Spine (Phila Pa 1976). 2011; 36(21 Suppl):S54-68. DOI: 10.1097/BRS.0b013e31822ef74d. View

12.

Russo M, Van Buyten J . 10-kHz High-Frequency SCS Therapy: A Clinical Summary. Pain Med. 2014; 16(5):934-42. PMC: 4660894. DOI: 10.1111/pme.12617. View

13.

Kregel J, Vuijk P, Descheemaeker F, Keizer D, van der Noord R, Nijs J . The Dutch Central Sensitization Inventory (CSI): Factor Analysis, Discriminative Power, and Test-Retest Reliability. Clin J Pain. 2015; 32(7):624-30. DOI: 10.1097/AJP.0000000000000306. View

14.

Murphy M, Fishman M . Differential target multiplexed spinal cord stimulator: a review of preclinical/clinical data and hardware advancement. Pain Manag. 2023; 13(4):233-242. DOI: 10.2217/pmt-2022-0052. View

15.

Mayer T, Neblett R, Cohen H, Howard K, Choi Y, Williams M . The development and psychometric validation of the central sensitization inventory. Pain Pract. 2011; 12(4):276-85. PMC: 3248986. DOI: 10.1111/j.1533-2500.2011.00493.x. View

16.

Goudman L, Bruzzo A, van de Sande J, Moens M . Goal Identification Before Spinal Cord Stimulation: A Qualitative Exploration in Potential Candidates. Pain Pract. 2019; 20(3):247-254. DOI: 10.1111/papr.12845. View

17.

Goudman L, Billot M, Duarte R, Eldabe S, Rigoard P, Moens M . Gradation of Clinical Holistic Response as New Composite Outcome to Evaluate Success in Spinal Cord Stimulation Studies for Pain. Neuromodulation. 2022; 26(1):139-146. DOI: 10.1016/j.neurom.2021.10.020. View

18.

Ogon M, Krismer M, Sollner W, Kantner-Rumplmair W, Lampe A . Chronic low back pain measurement with visual analogue scales in different settings. Pain. 1996; 64(3):425-428. DOI: 10.1016/0304-3959(95)00208-1. View

19.

Rademakers J, Maindal H, Steinsbekk A, Gensichen J, Brenk-Franz K, Hendriks M . Patient activation in Europe: an international comparison of psychometric properties and patients' scores on the short form Patient Activation Measure (PAM-13). BMC Health Serv Res. 2016; 16(1):570. PMC: 5059995. DOI: 10.1186/s12913-016-1828-1. View

20.

Kallewaard J, Billet B, Van Paesschen R, Smet I, Mendiola A, Pena I . European randomized controlled trial evaluating differential target multiplexed spinal cord stimulation and conventional medical management in subjects with persistent back pain ineligible for spine surgery: 24-month results. Eur J Pain. 2024; 28(10):1745-1761. DOI: 10.1002/ejp.2306. View